Genmab — November 2018

[E_L]

156One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone https://ash.confex.com/ash/2018/webprogram/Paper113183.html

[E_L]

After median follow-up of 27.8 months, median PFS was NR for D-VMP vs 19.1 months for VMP

[E_L]

trying to figure out which ones are most important, too many to post all here...

[E_L]

Griffin https://ash.confex.com/ash/2018/webprogram/Paper113122.html

[Bulder]

100% vgpr or better. så kører det

[E_L]

Genmabs release, a bit easier to find the important ones https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2018-ash-annual-meeting

[Solsen]

Thirty-five total abstracts on Genmab owned and partnered programs scheduled for presentation at ASH
•Three abstracts related to Genmab owned programs: DuoBody-CD3xCD20 & DuoHexaBody-CD37
•Daratumumab: 5 oral presentations; total of 30 accepted including ISS

[Solsen]

Imponerende !!!

[E_L]

sure is, Jan will be proud

[E_L]

To prove the anti-leukemic activity of daratumumab in AML in vivo https://ash.confex.com/ash/2018/webprogram/Paper113287.html

[StockBull]

Firework and champagne

[bibob]

Sagde han ikke også at de ville komme til at dominere ASH

[Bulder]

Lyra er med som oral!

[StockBull]

dominere i antal ser det ud til - forhåbentlig også i kvalitet af data

[E_L]

Conclusions: CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html

[bibob]

Vel ingen grund til at præsentere hvis data er dårlige

[E_L]

Conclusions:
CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. https://ash.confex.com/ash/2018/webprogram/Paper112375.html

[E_L]

Lyra : https://ash.confex.com/ash/2018/webprogram/Paper110310.html

[Solsen]

Addition of tretinoin (ATRA) induced a ~4-fold increase of CD38 expression in AML blasts and to a lower extent in normal donor cells. In fact, combination of tretinoin and daratumumab led to an enhanced anti-leukemic activity in AML - Vi mangler i den grad in vivo data og burde vel have dem nu !

[E_L]

we need some volunteers to just throw this into the clinic!